Clinical trials
Phase 3 Hypertension trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 7 |
| 2007 | 6 |
| 2008 | 7 |
| 2009 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Recruiting | 3 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 8 |
| AstraZeneca | 6 |
| Novartis Pharmaceuticals | 6 |
| Gilead Sciences | 3 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2 |
| Bristol-Myers Squibb | 2 |
| Mineralys Therapeutics Inc. | 2 |
| Novartis | 2 |
| United Therapeutics | 2 |
| Alnylam Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 47 |
| Cardiovascular Diseases | 6 |
| Pulmonary Arterial Hypertension | 4 |
| Heart Failure | 3 |
| Hypertension, Pulmonary | 3 |
| Renal Insufficiency, Chronic | 3 |
| Connective Tissue Diseases | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Familial Primary Pulmonary Hypertension | 2 |
| Kidney Failure, Chronic | 2 |
Trials
Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.